Can I Take Quercetin with Cytomel (Liothyronine)?

Why This Interaction Gets Flagged

Quercetin appears in drug interaction databases because of its well-documented CYP3A4 inhibitory activity. An in vitro study published in Pharmaceutical Research found quercetin inhibited CYP3A4 with an IC50 of approximately 1.97 µM, making it one of the more potent flavonoid inhibitors of this enzyme [1]. Interaction checkers apply this flag broadly to any drug that passes through the liver.

The CYP3A4 Question for Liothyronine

Liothyronine does not depend on CYP3A4 for its primary metabolism. T3 is cleared through three main routes: deiodination by type 3 deiodinase (D3), hepatic glucuronidation via UGT enzymes, and sulfation [2]. The American Thyroid Association (ATA) guidelines on hypothyroidism treatment note that thyroid hormones undergo sequential deiodination and conjugation, with renal and biliary excretion of metabolites [3]. CYP3A4 plays, at most, a minor accessory role.

Why It Still Matters

The flag is not entirely irrelevant. Quercetin also inhibits P-glycoprotein and OATP transporters in the intestinal wall [4]. These transporters influence oral absorption of many drugs, and any shift in liothyronine bioavailability, even a small one, matters because T3 has a narrow therapeutic index. A 10% to 15% swing in absorbed dose can push a patient from euthyroid to mildly thyrotoxic.

The Pharmacodynamic Concern: Quercetin and Thyroid Peroxidase

The more clinically meaningful interaction is pharmacodynamic. Quercetin directly inhibits thyroid peroxidase (TPO), the enzyme responsible for iodine organification and coupling of iodotyrosines into T4 and T3.

What the Cell Studies Show

Giuliani et al. (2014) demonstrated in FRTL-5 rat thyroid cells that quercetin at 10 µM significantly reduced TPO mRNA expression and suppressed sodium-iodide symporter (NIS) activity, effectively decreasing thyroid hormone synthesis capacity [5]. A 2012 study in Food and Chemical Toxicology confirmed that quercetin and other flavonoids inhibit TPO activity in a dose-dependent manner, with quercetin showing the strongest effect among tested compounds [6].

Clinical Translation

For patients taking exogenous T3 (liothyronine), TPO inhibition is less immediately dangerous because the drug bypasses the synthesis step entirely. You are already supplying the finished hormone. The concern applies more to patients who retain residual thyroid function and depend on endogenous production to supplement their medication dose. Many hypothyroid patients on liothyronine still produce some thyroid hormone, especially those on combination T4/T3 therapy or those with partial thyroidectomy.

Dr. Antonio Bianco, a professor of medicine at the University of Chicago and author of the ATA's T3 combination therapy position statements, has noted: "Residual thyroid function contributes meaningfully to circulating hormone levels in most hypothyroid patients. Anything that suppresses that residual output may require a compensatory dose adjustment" [7].

Absorption and Bioavailability Interactions

Liothyronine is well absorbed orally, with bioavailability estimated at 95% in fasted conditions [2]. That high baseline absorption limits the ceiling for quercetin-mediated increases via transporter inhibition. Still, the timing of co-ingestion matters.

Intestinal Transporter Effects

Quercetin's inhibition of P-gp has been demonstrated in human Caco-2 cell monolayers, where 50 µM quercetin increased the apparent permeability of P-gp substrates by 1.5 to 2.3 fold [4]. Whether this translates to clinical significance for a drug with 95% bioavailability is debatable. A pharmacokinetic study in healthy volunteers found that 500 mg quercetin increased the AUC of cyclosporine (a P-gp and CYP3A4 substrate) by approximately 36% [8]. Liothyronine is not cyclosporine, but the data establish that quercetin's transporter inhibition does reach clinically measurable levels at standard supplement doses.

Chelation and Binding

Flavonoids, including quercetin, can chelate metal ions. Thyroid hormone absorption is already sensitive to divalent cations (calcium, iron, aluminum). Quercetin's metal-binding properties add a theoretical risk of forming complexes that reduce T3 absorption in the gut lumen [9]. This effect is mitigated by dose separation.

Dose-Separation Strategy

Separating the two agents by time is the simplest risk-reduction measure. No randomized trial has tested quercetin-liothyronine spacing specifically, but the approach borrows from established guidance for thyroid hormone administration.

The 60-Minute Rule

The ATA recommends taking levothyroxine (T4) at least 60 minutes before breakfast or other medications to optimize absorption [3]. The same principle applies to liothyronine. Take your Cytomel dose first thing in the morning on an empty stomach. Wait at least 60 minutes before taking quercetin with food.

Patients on Split-Dose Liothyronine

Some clinicians prescribe liothyronine in divided doses (for example, 5 mcg twice daily) to smooth out the T3 peak. If you take a second dose in the afternoon, apply the same 60-minute separation from any quercetin dose. A practical schedule: liothyronine at 7 AM and 2 PM, quercetin with meals at 8:30 AM and 12:30 PM.

The Endocrine Society's clinical practice guideline on hypothyroidism states: "Medications and supplements that interfere with thyroid hormone absorption should be separated by at least one hour, and ideally four hours for agents with known chelation effects" [10].

Monitoring Recommendations

Baseline and Follow-Up Labs

Check free T3, free T4, and TSH before starting quercetin. Repeat these labs 8 to 12 weeks after initiating the supplement, and again if you change the quercetin dose. The narrow therapeutic window of T3 makes periodic monitoring non-negotiable.

What to Watch For

Symptoms of excess T3 (palpitations, tremor, heat intolerance, anxiety, insomnia) could indicate increased bioavailability or decreased clearance. Symptoms of insufficient T3 (fatigue, constipation, cold intolerance, weight gain) could indicate reduced absorption or increased endogenous suppression from TPO inhibition.

Specific Lab Targets

For most hypothyroid patients on liothyronine monotherapy, a free T3 in the upper third of the reference range (approximately 3.0 to 4.4 pg/mL, lab-dependent) with a TSH between 0.5 and 2.5 mIU/L represents a reasonable target. If free T3 rises above reference after adding quercetin, consider reducing the liothyronine dose by 5 mcg and rechecking in 6 weeks.

Quercetin Dose Considerations

Quercetin supplements typically range from 500 to 1,000 mg daily. Bioavailability of oral quercetin is low, estimated at 2% to 17% depending on the formulation [11]. Phytosome and liposomal formulations can increase absorption 20-fold compared to standard quercetin powder.

Low-Dose vs. High-Dose Risk

At 500 mg daily of standard quercetin, plasma concentrations rarely exceed 1 to 2 µM, which is near the lower threshold for CYP3A4 and TPO inhibition seen in vitro [1][5]. At 1,000 mg daily in enhanced-absorption formulations, plasma levels may reach 5 to 10 µM, placing them firmly in the range where enzyme inhibition becomes measurable.

The Practical Takeaway

If you choose to take quercetin with liothyronine, start with 500 mg daily of a standard (non-enhanced) formulation. Avoid jumping to high-dose liposomal quercetin without first establishing that your thyroid levels remain stable on the lower dose.

What If You Are Already Taking Both?

Do not stop either agent abruptly. Quercetin has no withdrawal syndrome, but suddenly removing a CYP3A4 and transporter inhibitor could shift liothyronine pharmacokinetics, potentially reducing bioavailability and causing a brief dip in T3 levels.

Step-by-Step Approach

1. Continue both at current doses.
2. Schedule thyroid labs (free T3, free T4, TSH) within the next 2 weeks.
3. Implement the 60-minute dose separation if you are not already doing so.
4. If labs are within target range and you feel well, no change is needed.
5. If free T3 is elevated or you have hyperthyroid symptoms, discuss a liothyronine dose reduction with your prescriber before discontinuing quercetin.

Special Populations

Patients on Combination T4/T3 Therapy

Patients taking both levothyroxine and liothyronine face a more complex picture. Quercetin's TPO inhibition could reduce residual endogenous T4 production, which in turn reduces substrate for peripheral T4-to-T3 conversion. The net effect on total T3 exposure depends on the ratio of exogenous to endogenous hormone. More frequent monitoring (every 6 to 8 weeks) is reasonable during the first 6 months of quercetin use in this group.

Post-Thyroidectomy Patients

Patients with no residual thyroid tissue (total thyroidectomy or radioactive iodine ablation) are entirely dependent on exogenous hormone. TPO inhibition is irrelevant for this group since there is no functional thyroid tissue remaining. The interaction risk is limited to the transporter and absorption effects described above, making it lower overall.

Patients Taking Quercetin for Mast Cell Activation or Allergies

Quercetin is commonly used as a natural antihistamine, particularly for mast cell activation syndrome (MCAS). These patients often take 1,000 to 2,000 mg daily in divided doses. At these higher doses, the interaction risk increases proportionally. A study in Molecular Nutrition & Food Research found that quercetin at 1,000 mg daily for 12 weeks reduced inflammatory markers (CRP decreased by 0.33 mg/L, P = 0.023) in overweight subjects [12]. The anti-inflammatory benefits may overlap with or complement thyroid treatment goals, but the higher dose demands tighter lab surveillance.

Drug-Supplement Interaction Classification

Based on available evidence, the quercetin-liothyronine interaction classifies as:

• Pharmacokinetic component: minor (CYP3A4 not a primary clearance pathway; transporter effects theoretically present but clinically small for a high-bioavailability drug)
• Pharmacodynamic component: moderate in patients with residual thyroid function (TPO inhibition); negligible in athyreotic patients
• Overall severity: low to moderate
• Management: dose separation, baseline and follow-up labs, symptom monitoring

The Natural Medicines Comprehensive Database rates flavonoid-thyroid interactions as "moderate" with a recommendation to "monitor closely" rather than "avoid" [13].